Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants

International Journal of Infectious Diseases

Volumn 15, Issue 4, 2011, Pages

  Kosalaraksa, Pope ^a   Thisyakorn, Usa ^b   Benjaponpitak, Suwat ^c   Chokephaibulkit, Kulkanya ^d   Santos Lima, Eduardo ^e  

^a KHON KAEN UNIVERSITY   (Thailand)

^b KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^c MAHIDOL UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e SANOFI PASTEUR   (France)

Author keywords

Co administration; Hexavalent; Hexaxim; Pediatric; Prevnar; Vaccine

Indexed keywords

DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HEPATITIS B ANTIGEN; HEXAXIM; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANOREXIA; ARTICLE; CRYING; FEVER; HUMAN; IMMUNOGENICITY; INFANT; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; IRRITABILITY; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROCONVERSION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SOMNOLENCE; VOMITING;

ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; DRUG THERAPY, COMBINATION; HAEMOPHILUS VACCINES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION SCHEDULE; INFANT; PNEUMOCOCCAL VACCINES; POLIOVIRUS VACCINE, INACTIVATED; THAILAND; TREATMENT OUTCOME; VACCINATION; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 79952696159     PISSN: 12019712     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijid.2010.12.004     Document Type: Article

References (32)

1. United Nations pre-qualified vaccines: WHO list of vaccines for purchase by UN agencies. Available at: (accessed July 20, 2010). http://www.who.int/immunization_standards/vaccine_quality/PQ_vaccine_list_en/en/index.html.
2. Vidor E., Plotkin S.A. Immunogenicity of a two-component (PT & FHA) acellular pertussis vaccine in various combinations. Hum Vaccin 2008, 4:328-340.
3. Diminsky D., Schirmbeck R., Reimann J., Barenholz Y. Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. Vaccine 1997, 15:637-647.
4. Tregnaghi M.W., Voelker R., Santos-Lima E., Zambrano B. Immunogenicity and safety of a novel yeast Hansenula polymorpha-derived recombinant hepatitis B candidate vaccine in healthy adolescents and adults aged 10-45 years. Vaccine 2010, 28:3595-3601.
5. Maçias M, Lanata C, Zambrano B, Santos-Lima E. Safety and immunogenicity of an investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine at 2, 4, 6 months compared to licensed vaccines in Latin America. Abstract 014. Presented at the 6th Congress of the World Society for Pediatric Infectious Diseases, Buenos Aires, Argentina, November 19-22, 2009.
6. Madhi S.A., Mitha I., Cutland C., Groome M., Santos-Lima E. Immunogenicity and safety of an investigational fully liquid hexavalent combination vaccine versus licensed combination vaccines at 6, 10, and 14 weeks of age in healthy South African infants. Pediatr Infect Dis J 2011, 30(4). doi:10.1097/INF.0b013e31820b93d2.
7. Tregnaghi MW, Zambrano B, Santos-Lima E. Immunogenicity and safety of an investigational hexavalent DTaP-IPV-Hep B-PRP-T vaccine at 2, 4, 6 months compared to licensed vaccines in Argentina. Abstract 013. Presented at the 6th Congress of the World Society for Pediatric Infectious Diseases, Buenos Aires, Argentina, November 19-22, 2009.
8. Bonmarin I., Levy-Bruhl D., Baron S., Guiso N., Njamkepo E., Caro V. Pertussis surveillance in French hospitals: results from a 10 year period. Euro Surveill 2007, 12(1).
9. Carlsson R.M., Trollfors B. Control of pertussis-lessons learnt from a 10-year surveillance programme in Sweden. Vaccine 2009, 27:5709-5718.
10. Olin P., Hallander H.O. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden. Euro Surveill 1999, 4:128-129.
11. Rendi-Wagner P., Paulke-Korinek M., Stanek G., Khanakah G., Kollaritsch H. Impact of a pertussis booster vaccination program in adolescents and adults on the epidemiology of pertussis in Austria. Pediatr Infect Dis J 2007, 26:806-810.
12. Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden with enhanced follow-up of cohorts immunized with acellular pertussis vaccines 2009. Appendix 2 SP-MSD. Solna,;1; Sweden: Swedish Institute for Infectious Disease Control; 2009. Available at: (accessed December 9, 2010). http://www.smittskyddsinstitutet.se/upload/Publikationer/11-y-report-app202-SPMSD.pdf.
13. Decker M., Bogaerts H., Edwards K., Plotkin S., Orenstein W., Offit P.A. Vaccines 2008, Saunders Co., Philadelphia, PA, p. 1069-101. 5th ed.
14. Edwards K.M., Decker M.D. Combination vaccines: hopes and challenges. Pediatr Infect Dis J 1994, 13:345-347.
15. Boot H.J., Schipper C.M. Simultaneous vaccination with Prevenar and multicomponent vaccines for children: interference or no interference?. Hum Vaccin 2009, 5:15-17.
16. Dagan R., Poolman J., Siegrist C.A. Glycoconjugate vaccines and immune interference: a review. Vaccine 2010, 28:5513-5523.
17. Schmitt H.J., Faber J., Lorenz I., Schmole-Thoma B., Ahlers N. The safety, reactogenicity and immunogenicity of a 7-valent pneumococcal conjugate vaccine (7VPnC) concurrently administered with a combination DTaP-IPV-Hib vaccine. Vaccine 2003, 21:3653-3662.
18. World Health Organization. Immunization profile-Thailand. Geneva: WHO; 2010. Available at: (accessed July 20, 2010). http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileresult.cfm.
19. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17:1055-1065.
20. Newcombe R.G. Interval estimation for the difference between independent proportions: comparison of eleven methods. Stat Med 1998, 17:873-890.
21. Newcombe R.G. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998, 17:857-872.
22. Farrington C.P., Manning G. Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk. Stat Med 1990, 9:1447-1454.
23. Kohl K.S., Marcy S.M., Blum M., Connell Jones M., Dagan R., Hansen J., et al. Fever after immunization: current concepts and improved future scientific understanding. Clin Infect Dis 2004, 39:389-394.
24. Kohl K.S., Magnus M., Ball R., Halsey N., Shadomy S., Farley T.A. Applicability, reliability, sensitivity, and specificity of six Brighton Collaboration standardized case definitions for adverse events following immunization. Vaccine 2008, 26:6349-6360.
25. Tichmann-Schumann I., Soemantri P., Behre U., Disselhoff J., Mahler H., Maechler G., et al. Immunogenicity and reactogenicity of four doses of diphtheria-tetanus-three-component acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccine coadministered with 7-valent pneumococcal conjugate Vaccine. Pediatr Infect Dis J 2005, 24:70-77.
26. Pichichero M.E., Blatter M.M., Reisinger K.S., Harrison C.J., Johnson C.E., Steinhoff M.C., et al. Impact of a birth dose of hepatitis B vaccine on the reactogenicity and immunogenicity of diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b combination vaccination. Pediatr Infect Dis J 2002, 21:854-859.
27. Brown R.D., Kearns G., Eichler V.F., Wilson J.T. A probability nomogram to predict rectal temperature in children. Clin Pediatr (Phila) 1992, 31:523-531.
28. Craig J.V., Lancaster G.A., Williamson P.R., Smyth R.L. Temperature measured at the axilla compared with rectum in children and young people: systematic review. BMJ 2000, 320:1174-1178.
29. Leick-Rude M.K., Bloom L.F. A comparison of temperature-taking methods in neonates. Neonatal Netw 1998, 17:21-37.
30. Robinson J.L., Seal R.F., Spady D.W., Joffres M.R. Comparison of esophageal, rectal, axillary, bladder, tympanic, and pulmonary artery temperatures in children. J Pediatr 1998, 133:553-556.
31. Carlsson R.M., Claesson B.A., Selstam U., Fagerlund E., Granstrom M., Blondeau C., et al. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998, 17:1026-1033.
32. Kanra G., Silier T., Yurdakok K., Yavuz T., Baskan S., Ulukol B., et al. Immunogenicity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTaP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine 1999, 18:947-954.